Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

120 participants · First posted Feb 23, 2017

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

24 participants · First posted Aug 24, 2021

First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

50 participants · First posted Oct 2, 2024

MDR-001

VED-001

VVX-001

Pelican Therapeutics, Inc.

United States

The State University of New York

United States

Friedrich Schiller University of Jena

Germany

Kura Oncology and Kyowa Kirin's Ziftomenib Achieves Primary Endpoints in Phase II AML Trial

Ziftomenib Achieves Primary Endpoint in Pivotal AML Trial, Kura and Kyowa Kirin Prepare FDA Filing

Kura Oncology's Ziftomenib Shows Promise in AML Treatment, Faces Competitive Landscape